Recent patents and advances in genomic biomarker discovery for colorectal cancers

Recent Patents on DNA and Gene Sequences

Volumn 4, Issue 2, 2010, Pages 86-93

  Chen, Qiyun ^a   Ye, Zhiyun ^b   Lin, Sheng Cai ^b   Lin, Biaoyang ^a,c,d  

^a ZHEJIANG UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c SWEDISH MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Colorectal cancer; Diagnosis; Epigenetic; miRNA; Mutation; Patent; Prognosis

Indexed keywords

ALX4 PROTEIN; BIOLOGICAL MARKER; CETUXIMAB; DNA METHYLTRANSFERASE INHIBITOR; DUAL SPECIFICITY PHOSPHATASE 6; EIF2S3 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOXL2 PROTEIN; GUANYLYL CYCLASE C; HISTONE DEACETYLASE INHIBITOR; ID4 PROTEIN; ITGA4 PROTEIN; K RAS PROTEIN; MICRORNA; MMD PROTEIN; MOLECULAR MARKER; NUCLEAR FACTOR I; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PROTEIN MDM2; RNF4 PROTEIN; SARM1 PROTEIN; SEPT9 PROTEIN; TFAP2E PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER GENETICS; CANCER STAGING; COLORECTAL CANCER; CPG ISLAND; DIAGNOSTIC ACCURACY; DNA DEGRADATION; DOWN REGULATION; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENOMICS; HUMAN; IMMUNE RESPONSE; MARKER GENE; NONHUMAN; PATENT; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; UPREGULATION;

COLORECTAL NEOPLASMS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENOME, HUMAN; HUMANS; MICRORNAS; MUTATION; PATENTS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 78649666066     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221510793205764     Document Type: Article

References (77)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4): 225-49.
2. Myers AP, Meyerhardt JA, Cantley LC. Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy? Clin Cancer Res 2009; 15(22): 6748-50.
3. Kanavos P, Schurer W. The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ 2010; Suppl 1: S115-29.
4. Schurer W, Kanavos P. Colorectal cancer management in the United Kingdom: current practice and challenges. Eur J Health Econ 2009; 10 (Suppl 1): S85-90.
5. Frascio F, Giacosa A. Role of endoscopy in staging colorectal cancer. Semin Surg Oncol 2001; 20(2): 82-5.
6. Kung JW, Levine MS, Glick SN, Lakhani P, Rubesin SE, Laufer I. Colorectal cancer: screening double-contrast barium enema examination in average-risk adults older than 50 years. Radiology 2006; 240(3): 725-35.
7. Neri E, Faggioni L, Cerri F, Turini F, Angeli S, Cini, L, et al. CT colonography versus double-contrast barium enema for screening of colorectal cancer: comparison of radiation burden. Abdom Imaging 2009 [Epub ahead of print].
8. Arnesen RB, von Benzon E, Adamsen S, Svendsen LB, Raaschou HO, Hansen OH. Diagnostic performance of computed tomography colonography and colonoscopy: a prospective and validated analysis of 231 paired examinations. Acta Radiol 2007; 48(8): 831-7.
9. Kaminski MF, Regula J. Colorectal cancer screening by colonoscopy-- current issues. Digestion 2007; 76(1): 20-5.
10. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130(6): 1872-85.
11. Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res 1996; 87(10): 1011-24.
12. Saito H. Sensitivity of immunochemical occult blood testing in detecting early colorectal cancer. Nippon Rinsho 1996: 54(5); 1421-4.
13. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature 2000; 405(6788): 827-36.
14. Davison TS, Johnson CD, Andruss BF. Analyzing micro-RNA expression using microarrays. Methods Enzymol 2006; 411: 14-34.
15. Shinawi M, Cheung SW. The array CGH and its clinical applications. Drug Discov Today 2008; 13(17-18): 760-70.
16. Lin B, Wang J, Cheng Y. Recent patents and advances in the nextgeneration sequencing technologies. Recent Pat Biomed Eng 2008; 1(1): 60-7.
17. Ansorge WJ. Next-generation DNA sequencing techniques. N Biotechnol 2009; 25(4): 195-203.
18. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008; 9: 387-402.
19. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422(6928): 198-207.
20. Findeisen P, Neumaier M. Mass spectrometry-based clinical proteomics profiling: current status and future directions. Expert Rev Proteomics 2009; 6(5): 457-9.
21. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58(22): 5248-57.
22. Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg 2006; 93(4): 395-406.
23. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23(3): 609-18.
24. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009; 45(10): 1890-6.
25. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret, GY, Morere JF. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res 2009; 29(5): 1615-20.
26. Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn 2005; 5(5): 701-13.
27. Shuber, A.P. Methods for detecting nucleic acids indicative of cancer. US20056964846 (2005).
28. Terng, H.-J., Lee, W.-J., Chen, C.-Y. Molecular markers for lung and colorectal carcinomas. WO2010033371 (2010).
29. Carvalho, B.P.M.D., Meijer, G.A. Methods and compositions for diag-nosing and treating a colorectal adenocarcinoma. WO2010032177 (2010).
30. Chant, J., Guerrero, A.S., Haverty, P., Honchell, C., Jung, K., Wu, T. Methods and compositions for the diagnosis and treatment of cancer. US20090311250 (2009).
31. Slamon, D.J., Anderson, L.A., Ginther, C.L. Amplified and overexpressed gene in colorectal cancers. US7537905 (2009).
32. Christensen LL, Madsen BE, Wikman FP, Wiuf C, Koed K, Tjonneland A, et al. The association between genetic variants in hMLH1 and hMSH2 and the development of sporadic colorectal cancer in the Danish population. BMC Med Genet 2008; 9: 52.
33. Mitchell RJ, Farrington SM, Dunlop MG, Campbell H. Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review. Am J Epidemiol 2002; 156(10): 885-902.
34. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28(7): 1181-9.
35. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361(1); 98-9.
36. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 2009; 115(16): 3609-17.
37. di Fiore F, Charbonnier F, Lefebure B, Laurent M, Le Pessot F, Michel P, et al. Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer 2008; 99(3): 551-2.
38. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27(12): 2091-6.
39. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97(18): 1139-45.
40. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15(9): 3184-8.
41. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20(1): 84-90.
42. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69(5): 1851-7.
43. Robbins, P.F., Rosenberg, S.A., Maccalli, C. Colorectal Cancer Antigen. US20090311279 (2009).
44. Teng, D.H.-F., Tavtigian, S.V., Perry III, W. L., Skolnick, M.H. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer. US20095989885 (2009).
45. Stein, U., Walther, W, Arlt, F., Schlag, P.M. Methods for diagnosing metastasis by analyzing mutations in??-catenin. WO2008037432 (2008).
46. Ausch C, Kim YH, Tsuchiya KD, Dzieciatkowski S, Washington MK, Paraskeva C, et al. Comparative analysis of PCR-based biomarker assay methods for colorectal polyp detection from fecal DNA. Clin Chem 2009; 55(8): 1559-63.
47. Lofton-Day, C., Ebert, M. Methods and nucleic acids for the detection of colorectal cell proliferative disorders. EP003380 (2007).
48. Tetzner, R., Sledziewski, A., Lofton-Day, C., Distler, J., Model, F., Payne, S. Methods and nucleic acids for analyses of cellular proliferative disorders. EP006538 (2008).
49. Distler, J., Hildmann, T., Lesche, R., Lofton-Day, C., Model, F., Schuster, M., Sledziewski, A., Song, X., Tetzner, R. Methods and nucleic acids for analyses of cellular proliferative disorders. US2006014131 (2006).
50. Feinberg, A. Method for identifying cancer risk. US2003023725 (2004).
51. Hoon, D.S.B., Umetani, N. Use of ID4 for diagnosis and treatment of cancer. US20097588894 (2009).
52. Baylin, S.B., Herman, J., Suzuki, H. Genomic screen for epigenetically silenced genes associated with cancer. US20030224040 (2003).
53. Baylin, S.B., Herman, J., Suzuki, H. Genomic screen for epigenetically silenced genes associated with cancer. US20090099037 (2009).
54. Baylin, S.B., Criekinge, W.V., Schuebel, K.E. Early detection and prognosis of colon cancers. US20080221056 (2008).
55. Laird, P., Siegmund, K.D., Campan, M., Weisenberg, D.J., Long, T.I. DNA methylation markers associated with the CpG island methylator phenotype (CIMP) in human colorectal cancer. US20090053706 (2009).
56. Esteller, M. Methylation detection. US20090176655 (2009).
57. Bandres, E., Cubedo, E., Agirre, X., Malumbres, R., Zarate, R., Ramirez, N., Abajo, A., Navarro, A., Moreno, I., Monzo, M., Garcia-Foncillas, J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and nontumoral tissues. Mol Cancer 2006; 5: 29.
58. Cummins, J.M., He, Y., Leary, R.J., Pagliarini, R., Diaz, L.A., Jr. Sjoblom, T., Barad, O., Bentwich, Z., Szafranska, A.E., Labourier, E., Raymond, C.K., Roberts, B.S., Juhl, H., Kinzler, K.W., Vogelstein, B., Velculescu, V.E. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103(10): 3687-92.
59. Yang, L., Belaguli, N., Berger, D.H. MicroRNA and colorectal cancer. World J Surg 2009; 33(4): 638-46.
60. Mambo, E., Davison, T., Lebourgeois, P.A. MicroRNA markers for recurrence of colorectal cancer. US2009036195 (2009).
61. Brenner, B., Gilad, S., Goren, Y., Chajut, A. Methods and compositions for detecting colorectal cancer. WO2010004562 (2010).
62. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2009: 127(1): 118-126.
63. Raponi, M., Arndt, G.M. Process for monitoring colorectal cancer. US20100075304 (2010).
64. Mandrekar, S.J., Sargent, D.J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009; 27(24): 4027-34.
65. Rifai, N., Gillette, M.A., Carr, S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006; 24(8): 971-83.
66. Barker, P.E. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann N Y Acad Sci 2003; 983: 142-50.
67. Lee BB, Lee EJ, Jung EH, Chun HK, Chang DK, Song SY et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009; 15(19): 6185-91.
68. Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH. Clinicopathological features of CpG island methylator phenotypepositive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008; 58(2): 104-13.
69. Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, et al. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer 2010 [Epub ahead of print].
70. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10(6): 534-41.
71. Ang PW, Li WQ, Soong R, Iacopetta B. BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients. Cancer Lett 2009; 273(2): 221-4.
72. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306(5696): 640-3.
73. Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, et al. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 2005; 65(8): 3081-91.
74. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria, D, et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 2009; 27(2): 199-204.
75. Chuang HY, Lee E, Liu YT, Lee D. Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007; 3: 140.
76. Park J, Lee DS, Christakis NA, Barabasi AL. The impact of cellular networks on disease comorbidity. Mol Syst Biol 2009; 5: 262.
77. Jin G, Zhou X, Wang H, Zhao H, Cui K, Zhang XS, et al. The knowledge-integrated network biomarkers discovery for major adverse cardiac events. J Proteome Res 2008; 7(9): 4013-21.